secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPID MICRO BIOSYSTEMS, INC. (RPID)
CIK:        0001380106
Form:       8-K
Filed at:   2024-08-02T23:59:59+00:00
Accession:  0001380106-24-000162
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapid Micro Biosystems Q2 revenue up 32% to $6.6M; Nasdaq transfer due to bid price deficiency
--------------------------------------------------------------------------------

- Q2 revenue $6.6M (+32% YoY); net loss $12.6M ($0.29 loss per share) vs $14.0M loss a year ago.
- Gross margin improved 35pp vs Q2 2023; five Growth Direct systems placed; 150th system with top 15 pharma.
- Operational efficiency program: ~$7M annual savings; workforce reduction; aiming for positive cash flow by end-2027.
- Stock to transfer from Nasdaq Global Select to Nasdaq Capital Market on Aug 5 due to bid price <$1; 180-day compliance period.
- Reaffirms FY2024 revenue guidance >=$27M (>=20% growth) and at least 20 system placements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1380106/000138010624000162/0001380106-24-000162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1380106/000138010624000162/rpid-20240802.htm
  HTML page:      https://secwatch.observer/filing/0001380106-24-000162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer